Crinetics will host an investor conference call on June 3, 2024, at 4:30 pm Eastern Time to discuss the initial findings for atumelnant in two ongoing, open-label studies.
News & Events
Crinetics Pharmaceuticals Announces Positive Initial Findings for Atumelnant in Congenital Adrenal Hyperplasia and ACTH-Dependent Cushing’s Syndrome
Transforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine care.